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spirometry, BDR and FeNO testing. Where diagnostic uncertainty remained, indi-
viduals would then undergo PEF and finally MCT testing. This strategy dominated 
other strategies that did not utilise MCT, producing higher health outcomes at a 
lower cost to the health service. Two strategies that made more individuals undergo 
MCT were not cost-effective at the threshold with incremental cost-effectiveness 
ratios of £20,276 and £32,565 per/QALY respectively. Although assumptions were 
made relating to conditional dependence and the consequences of false diagnoses, 
the model’s results were found to be robust to significant changes in these and 
other uncertain parameters. ConClusions: These findings highlight the need for 
thorough objective testing for diagnosing asthma as doing so has the potential to 
improve health outcomes whilst reducing costs to the health service.
PMD97
Risk FactoRs FoR DeveloPing Diabetes as a DeteRMinant oF the cost-
eFFectiveness oF Using coRonaRy calciUM scoRe to gUiDe PRiMaRy 
PRevention With statins
Silva Miguel L1, Ferreira AM2
1CISEP (Research Centre on the Portuguese Economy), Lisbon, Portugal, 2Hospital de Santa Cruz 
and Hospital da Luz, Carnaxide and Lisbon, Portugal
objeCtives: The determination of coronary calcium score allows to identify indi-
viduals for which primary prevention with statins may be unnecessary. In this 
study it is shown that the presence of risk factors for developing diabetes interacts 
with the benefits of this identification. Methods: A Markov model was used to 
estimate the evolution of two cohorts with elevated C-reactive protein and low 
LDL cholesterol: one without risk factors for developing diabetes and another with 
those risk factors. The progression of both cohorts was simulated assuming four 
alternative strategies: “no treatment”, “treat if score> 100”, “treat if score> 0” and 
“treat all”. Results: For individuals without risk factors for diabetes, the “treat all” 
strategy is the most expensive but allows to achieve better clinical outcomes, with a 
cost per QALY of 24,164€ vs. the strategy “treat if score> 0”. For those with risk factors 
for diabetes, the strategy “treat all” remains the most expensive, but the decrease in 
coronary events does not compensate the increase in diabetes incidence, whereby 
the strategy “treat all” is dominated by “treat if score> 0”. The cost per QALY of this 
latter strategy in comparison to “treat if score> 100” is 36,034€ . Deterministic and 
probabilistic sensitivity analysis show that results are robust. ConClusions: The 
presence of risk factors for diabetes affects the cost-effectiveness of using coronary 
calcium score as a guide to implement primary prevention in this population.
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objeCtives: Each year approximately 900,000 new cases of hematological malig-
nancies are diagnosed globally. Diagnosis is comprised of multiple modalities, 
including flow cytometry. Current laboratory developed testing (LDT) for flow cytom-
etry is non-standardized and error prone. Insufficient research has been published 
evaluating the cost and errors in this space. Manual work, including steps such as 
antibody selection, compensation, and pipetting have been identified as potential 
sources of error in flow cytometry. The aim of this study is to quantify the time 
and associated economic impact of manual work in a flow cytometry process for 
hematological malignancies. Methods: An observational study was conducted at a 
public Canadian acute care clinical laboratory in collaboration with a lean specialist 
team for the purposes of workflow analysis. The results of this pilot were used to 
inform this extended costing analysis. Evaluation of the instrument, reagent, and 
sample preparation was performed. Total opportunities for error in the workflow 
were identified (defined as steps involving manual efforts) and manual labor time 
was then used to estimate indirect costs. Results: A total of 37 steps were involved 
in instrument set-up, 81 steps for manual reagent and sample preparation, each 
of these steps containing multiple opportunities for error. At a 550 bed institution 
performing 591 leukemia and lymphoma tests annually, it was estimated that a 
total of 365 hours of manual labor by a skilled medical lab technologist incurred 
indirect costs of $18,250. ConClusions: Based on this case study, manual work 
resulted in substantial cost to the laboratory in indirect costs. This suggests that 
in addition to reducing the potential for error, minimizing unnecessary manual 
steps in the flow cytometry workflow could also reduce laboratory indirect costs 
and improve efficiency. Future research is warranted to quantify the frequency of 
errors in manual steps in LDT for flow cytometry.
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objeCtives: Human epidermal growth factor receptor 2 (HER2) status identifi-
cation is established by immunohistochemistry and in situ hybridisation (ISH). 
Silver in situ hybridisation (SISH) is an alternative technique to the fluorescence in 
situ hybridization (FISH). Both methods are recommended by American Society of 
Clinical Oncology (ASCO)/College of American Pathologists (CAP) 2013 guidelines. 
The primary aim of this analysis is to evaluate the economical and organizational 
impact by adopting FISH or SISH test for HER2 testing. Methods: We conducted 
an analysis to evaluate costs, times (laboratory personnel working hours) and 
laboratory-space to process a sample using the manual method (FISH) compared 
to the automated system (SISH). The analysis was performed from the pathology 
laboratory’s perspective. We analysed the complete workflow (laboratory personnel 
and medical resource used) to perform the two tests (FISH and SISH) during pathol-
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objeCtives: The majority of patients who get an implantable cardioverter defi-
brillator (ICD) for primary prevention of sudden cardiac death (SCD) never need to 
receive appropriate ICD therapies. Better risk-stratifying tools are thus needed to 
improve the cost-effectiveness of device implantation. The purpose of this study 
was to assess the cost-effectiveness of using delayed enhancement cardiac mag-
netic resonance (CMR) to refine patient selection for ICD therapy in primary pre-
vention. Methods: A Markov model was developed to assess long-term survival, 
quality-adjusted life years (QALYs), and lifetime costs for a cohort of patients with 
reduced left ventricular ejection fraction without previous ventricular arrhythmias. 
Two different strategies were compared: A) implant an ICD in all patients (“ICD for 
all”); and B) perform CMR and implant an ICD only in patients with delayed enhance-
ment exceeding 5% of myocardial mass (“CMR-guided ICD”). Clinical and economic 
inputs were derived from European representative literature. Results: The “ICD 
for all” strategy led to a total cost of 68,818€ and 7.0 QALY per patient, implying an 
incremental cost of 7,372€ and allowing a gain of 0.1 QALY when compared to the 
strategy “CMR-guided ICD”. Consequently, the cost-utility ratio is 77,943€ per QALY. 
Probabilistic sensitivity analysis showed that, assuming a willingness to pay of 
50,000€ per QALY, the “ICD for all” strategy would be cost-effective in 31 % of the sim-
ulations. ConClusions: Results suggest that implanting ICD in selected patients 
allows to use this device in those that benefit most, improving the cost-effectiveness 
of ICD implantation for the primary prevention of sudden cardiac death.
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objeCtives: Mutations in BRCA1 and BRCA2 genes are associated with an increased 
risk of breast and ovarian cancer. If a BRCA mutation is detected in women with 
ovarian cancer their unaffected relatives may be offered genetic testing and pro-
phylactic surgery. The long-term cost-effectiveness of providing BRCA testing to 
women with ovarian cancer and to their unaffected female first-degree relatives 
in the UK has previously been evaluated using a lifetime Markov model, but the 
approach had a number of limitations. The current study will employ a hybrid dis-
crete event simulation (DES) structure that addresses some of the Markovian limi-
tations associated with the previous model and will differentiate between BRCA1 
and BRCA2 mutations and will consider results for a number of possible UK family 
pedigrees. Methods: A hybrid DES will be constructed with a lifetime horizon, 
to evaluate the cost-effectiveness of BRCA testing in women with ovarian cancer 
and their female first- and second-degree relatives versus no testing. The model 
will consider the incidence of ovarian and breast cancer, differentiating between 
those with BRCA1 and BRCA2 mutations, as well as the associated mortality rates. 
Individuals identified as BRCA1 or BRCA2 positive will be eligible to undergo bilat-
eral mastectomy and bilateral salpingo-oophorectomy, which significantly reduce 
the risk of both ovarian and breast cancer. Results: Results will be presented as 
an incremental cost-effectiveness ratio expressed as a cost per quality adjusted 
life year (QALY). These will be compared to the UK cost-effectiveness threshold of 
£20,000 per QALY gained. A number of sensitivity and subgroup analyses will be 
presented alongside the base case. ConClusions: We aim to demonstrate that 
screening patients with ovarian cancer and their first- and second-degree relatives 
for the BRCA1 and BRCA2 mutation is cost-effective and reduces the incidence of 
breast and ovarian cancer in the population.
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objeCtives: To develop an economic model to inform recommendations on the 
optimal diagnostic pathway for the recent clinical guideline on the diagnosis and 
monitoring of asthma, commissioned by the National Institute for Health and Care 
Excellence (NICE). Methods: A de-novo economic model evaluated current prac-
tice alongside six diagnostic pathways comprising of the following tests: spirometry, 
bronchodilator reversibility (BDR), peak expiratory flow (PEF), fractional exhaled 
nitric oxide (FeNO) and methacholine/histamine challenge testing (MCT). A model 
was developed using a decision tree to identify what proportion of individuals would 
receive a correct (true positive, true negative) or incorrect (false positive, false nega-
tive) diagnosis, utilising diagnostic accuracy data in adults from systematic reviews 
conducted for each test. These proportions fed into one of four Markov models, 
depending on the diagnosis, which calculated final health and cost outcomes. The 
model explored the impact of alternative false diagnoses, such as chronic obstruc-
tive pulmonary disease, and applied modelling techniques to account for the effect 
of conditional dependence on diagnostic accuracies. Results: The most cost-effec-
tive strategy at a £20,000 per/QALY threshold consisted of all individuals undergoing 
